Crux Biomedical Overview

  • Year Founded
  • 2004

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $39M

  • Investors
  • 1

Crux Biomedical General Information

Description

Developer of a preventive device for pulmonary embolisms. The company provide Crux VCF System, that stops the blood clots from reaching the lungs. It is useful for patients at risk of pulmonary embolism who can't tolerate blood thinners, method of preventing clots.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1455 Adams Drive
  • Suite 1170
  • Menlo Park, CA 94025
  • United States
+1 (650)
Primary Industry
Surgical Devices
Acquirer
Vertical(s)
Corporate Office
  • 1455 Adams Drive
  • Suite 1170
  • Menlo Park, CA 94025
  • United States
+1 (650)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crux Biomedical Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 12-Dec-2012 $39M Completed Generating Revenue
6. Later Stage VC (Series D) 07-Jun-2011 Completed Generating Revenue
5. Later Stage VC (Series C) 01-Mar-2011 Completed Generating Revenue
4. Later Stage VC 22-Jan-2009 Completed Generating Revenue
3. Later Stage VC 08-Dec-2008 Completed Generating Revenue
2. Early Stage VC (Series B) 02-Oct-2007 $2.5M $6.35M Completed Generating Revenue
1. Early Stage VC (Series A) 18-Sep-2006 $3.85M $3.85M Completed Product Development
To view Crux Biomedical’s complete valuation and funding history, request access »

Crux Biomedical Patents

Crux Biomedical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160066880-A1 Distal protection systems and methods with pressure and ultrasound features Active 15-Mar-2013
US-20160022292-A1 Retrieval and centering device and method with pressure and ultrasound features Inactive 15-Mar-2013
US-10213288-B2 Distal protection filter Active 06-Mar-2012
US-20130238010-A1 Distal protection filter Active 06-Mar-2012
US-10433945-B2 Retrieval snare device and method Active 13-Jan-2012 A61F2/01
To view Crux Biomedical’s complete patent history, request access »

Crux Biomedical Former Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alloy Ventures Venture Capital Minority
Emergent Medical Partners Venture Capital Minority
Hercules Capital Lender/Debt Provider Minority
Three Arch Partners Venture Capital Minority
To view Crux Biomedical’s complete investors history, request access »

Crux Biomedical FAQs

  • When was Crux Biomedical founded?

    Crux Biomedical was founded in 2004.

  • Where is Crux Biomedical headquartered?

    Crux Biomedical is headquartered in Menlo Park, CA.

  • What industry is Crux Biomedical in?

    Crux Biomedical’s primary industry is Surgical Devices.

  • Is Crux Biomedical a private or public company?

    Crux Biomedical is a Private company.

  • What is the current valuation of Crux Biomedical?

    The current valuation of Crux Biomedical is .

  • What is Crux Biomedical’s current revenue?

    The current revenue for Crux Biomedical is .

  • How much funding has Crux Biomedical raised over time?

    Crux Biomedical has raised $30.6M.

  • Who are Crux Biomedical’s investors?

    Alloy Ventures, Emergent Medical Partners, Hercules Capital, and Three Arch Partners have invested in Crux Biomedical.

  • When was Crux Biomedical acquired?

    Crux Biomedical was acquired on 12-Dec-2012.

  • Who acquired Crux Biomedical?

    Crux Biomedical was acquired by Volcano.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »